


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Original) 2-(α -n-pentanonyl)benzoates having the following formula



wherein n is 1 or 2; M is a monovalent metal ion, a bivalent metal ion or an organic base group.

2. (Previously Presented) The 2-(α -n-pentanonyl)benzoates of claim 1, wherein M is a monovalent metal ion selected from the group consisting of Li⁺, Na⁺ and K⁺.

Claims 3-10. (Cancelled)

11. (Previously Presented) The 2-(α -n-pentanonyl)benzoates of claim 1, wherein M is a bivalent metal ion selected from the group consisting of Mg²⁺, Ca²⁺ and Zn²⁺.

12. (Previously Presented) The 2-(α -n-pentanonyl)benzoates of claim 1, wherein M is an organic base group selected from the group consisting of benzyl amine, t-butyl amine, methyl benzyl amine and N,N'-dibenzylethylenediamine.

13. (Previously Presented) The 2-(α -n-pentanonyl)benzoates of claim 1, wherein M is selected from the group consisting of Na⁺, K⁺, Ca²⁺, and N,N'-dibenzylethylenediamine.

14. (Previously Presented) A method for preparing the 2-(α -n-pentanonyl)benzoates of claim 1, wherein M is an organic base group, said method comprises:

- hydrolyzing 3-n-butenylphthalide under an alkaline condition;
- acidifying the hydrolyzed product to obtain 2-(α -n-pentanonyl)benzoic acid;
- dissolving the 2-(α -n-pentanonyl)benzoic acid in a solvent with low polarity and then reacting with an organic base to form a salt; and
- separating out the salt.

15. (Previously Presented) The method of claim 14, wherein the solvent with low polarity comprises benzenes, ethers, dichloromethane, and ethyl acetate.

16. (Currently Amended) The method of claim 14, ~~wherein M is selected from the group consisting of Na⁺, K⁺, Ca²⁺, and N,N'-dibenzylethylenediamine~~ wherein M is an organic base group selected from the group consisting of benzyl amine, t-butyl amine, methyl benzyl amine and N,N'-dibenzylethylenediamine.

17. (Previously Presented) A method for preparing the 2-(α -n-pentanonyl)benzoates of claim 1, wherein M is a monovalent metal ion, said method comprises:

- hydrolyzing 3-n-butenylphthalide under an alkaline condition;
- acidifying the hydrolyzed product to obtain 2-(α -n-pentanonyl)benzoic acid;
- reacting the 2-(α -n-pentanonyl)benzoic acid with a metal ionic base dissolved in a solvent with high polarity to form a salt, and then adding a solvent with low polarity under stirring; and
- separating out the salt.

18. (Previously Presented) The method of claim 17, wherein the solvent with high polarity comprises C1-C4 lower alcohols, and wherein the solvent with low polarity comprises benzenes, ethers, dichloromethane, and ethyl acetate.

19. (Previously Presented) The method of claim 17, wherein M is a monovalent metal ion selected from the group consisting of Li^+ , Na^+ and K^+ .
20. (Previously Presented) The method of 14, wherein the solvent with low polarity is ethyl ether.
21. (Previously Presented) The method of claim 17, wherein the solvent with low polarity is ethyl ether, and the solvent with high polarity is methanol.
22. (Previously Presented) A method for preparing the 2-(α -n-pentanonyl)benzoates of claim 1, wherein M is a bivalent metal ion, said method comprising mixing a solution of 2-(α -n-pentanonyl)benzoates with a solution of bivalent metal ion salt, performing trans-salification to obtain 2-(α -n-pentanonyl)benzoates of bivalent metal ion.
23. (Previously Presented) The method as claimed in claim 22, wherein M is a bivalent metal ion selected from the group consisting of Mg^{2+} , Ca^{2+} and Zn^{2+} .
24. (Previously Presented) A method for treating or preventing cardio-cerebral ischemic diseases, alleviating the disturbance of cardio-cerebral circulation and inhibiting thrombosis in a subject, comprising administering to a subject a therapeutically effective amount of the 2-(α -n-pentanonyl)benzoates of claim 1.
25. (Previously Presented) A pharmaceutical composition for treating or preventing cardio-cerebral ischemic diseases, alleviating the disturbance of cardio-cerebral circulation and inhibiting thrombosis, comprising a therapeutically effective amount of the 2-(α -n-pentanonyl)benzoates of claim 1, and one or more pharmaceutically acceptable carriers.
26. (Previously Presented) The pharmaceutical composition of claim 25, which is formulated into tablets, capsules, granules, intravenous injections, or lyophilized intravenous injections.